AstraZeneca now sees FY24 core EPS to increase by mid teens percentage

AstraZeneca stated: “Due to strong underlying growth in Product Sales and Alliance Revenue, the Company raises its Total Revenue and Core EPS guidance for FY 2024 at CER, based on the average foreign exchange rates through 2023. Total Revenue is expected to increase by a mid teens percentage, previously a low double-digit to low teens percentage. Core EPS is expected to increase by a mid teens percentage, previously a low double-digit to low teens percentage.”